TOP TIERMARKET NEWSWIRE

News & sentiment

MACROGENICS INC (MGNX) — News & AI sentiment

MACROGENICS INC (MGNX) news roundup. 5 stories in the past week, 7 over 30 days. Average 30-day sentiment is 59/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $129K — net selling of $129K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

5

avg sentiment 59.4/100

30d stories

7

avg sentiment 59/100

Insider net (90d)

$129K

0 buys · 1 sells

Congress (90d)

0

0 buys · 0 sells

MGNX news in the last 24 hours, 7 days, 30 days and 90 days

How much MGNX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	MGNX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	5	59.4/100	MGNX headlines →
Last 30 days	7	59/100	MGNX headlines →
Last 90 days	20	58.6/100	MGNX headlines →

Latest stories on MGNX

MacroGenics announces interim data from LINNET study evaluating lorigerlimab

The Fly58 · neutralproduct/pr

2d ago

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

StockTitan67 · bullishproduct/pr

2d ago

MACROGENICS INC (MGNX) files 8-K

SEC 8-K50 · neutralgeneral

5d ago

MacroGenics announces interim data from MGC026 study

The Fly58 · neutralproduct/pr

5d ago

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

StockTitan64 · neutralproduct/pr

5d ago

MacroGenics doses first patient in MGC030 study

The Fly58 · neutralproduct/pr

Oct 15

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

Business Insider58 · neutralproduct/pr

Oct 15

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Business Insider56 · neutralgeneral

Sep 9

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

Seeking Alpha63 · neutralproduct/pr

Sep 9

8-K/A - MACROGENICS INC (MGNX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 3

MacroGenics price target raised to $11 from $9 at B. Riley

The Fly61 · neutralanalyst

Aug 17

MacroGenics receives $10M milestone after Gilead exercises license option

The Fly63 · neutralgeneral

Aug 17

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Yahoo Top67 · bullishproduct/pr

Aug 15

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

Seeking Alpha28 · bearishearnings

Aug 13

MACROGENICS INC (MGNX) files 8-K

SEC 8-K50 · neutralgeneral

Aug 13

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

GlobeNewswire63 · neutralearnings

Aug 13

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

StockTitan63 · neutralearnings

Aug 13

MacroGenics stock rises on $10M Gilead option exercise

Investing.com Markets63 · neutralgeneral

Aug 11

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

GlobeNewswire67 · bullishgeneral

Aug 11

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

Business Insider65 · bullishgeneral

Aug 11

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

Seeking Alpha56 · neutralgeneral

Jul 27

Citizens reiterates MacroGenics stock rating ahead of ESMO data

Investing.com Analyst Ratings56 · neutralanalyst

Jul 27

MacroGenics slips after early-stage trial data for lead asset

Seeking Alpha34 · bearishgeneral

Jul 24

MACROGENICS INC (MGNX) files 8-K

SEC 8-K50 · neutralgeneral

Jul 23

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

StockTitan56 · neutralproduct/pr

Jul 23

Open MGNX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →